Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional Results available

A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

ClinicalTrials.gov ID: NCT04179864

Public ClinicalTrials.gov record NCT04179864. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 6:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer

Study identification

NCT ID
NCT04179864
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Epizyme, Inc.
Industry
Enrollment
102 participants

Conditions and interventions

Interventions

  • Abiraterone/prednisone Drug
  • Enzalutamide Drug
  • Tazemetostat Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 17, 2019
Primary completion
Nov 3, 2024
Completion
Nov 3, 2024
Last update posted
Mar 9, 2026

2019 – 2024

United States locations

U.S. sites
16
U.S. states
10
U.S. cities
15
Facility City State ZIP Site status
Genesis Healthcare Partners San Diego California 92123
The Urology Center Of Colorado Denver Colorado 80211
Hematology Oncology Associates of the Treasure Coast Port Saint Lucie Florida 34952
XCancer - Northwest Oncology and Hematology Rolling Meadows Illinois 60008
Dana Farber Cancer Institute Boston Massachusetts 02115
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Comprehensive Cancer Centers of Nevada - Central Valley Las Vegas Nevada 89169
Memorial Sloan Kettering Cancer Center New York New York 10065
Associated Medical Professionals of NY, PLLC - Urology Syracuse New York 13210
Montefiore Einstein Center for Cancer Care The Bronx New York 10461
University of Pittsburgh Medical Center - Hillman Cancer Center Pittsburgh Pennsylvania 15232
SCRI - Tennessee Oncology Chattanooga Chattanooga Tennessee 37404
Urology Associates P.C. Hendersonville Tennessee 37075
XCancer - Tennesee Cancer Specialists Knoxville Tennessee 37909
SCRI - Tennessee Oncology Nashville Nashville Tennessee 37203
Urology San Antonio San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04179864, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04179864 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →